Screens shrink children's brains
MRI scans of preschoolers show thinner grey matter in areas tied to language, memory and empathy - with heavy screen users falling behind in reading and attention skills.
Even toddlers with three hours of daily screen time can lag behind when it comes to vocabulary and pre-school readiness.
Leading paediatricians fear that real-world play is being removed from children's lives in favour of screens and have warned that tots who spend seven to eight hours fixated on screens per day are at risk of tunnel vision and concentration issues.
The stiffening of eye muscles can lead to behaviour problems that are often confused with attention deficit hyperactivity disorder (ADHD).
Sir Cary Cooper, a psychology professor at the University of Manchester, said: "Children are using these devices and they are not learning social and non-verbal skills that we pick up from interacting, face-to-face, with other people."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
a day ago
- Sydney Morning Herald
They built a billion-dollar start-up from their garage. Now they're going again
They created one of Australia's most valuable technology start-ups in a Brisbane garage – Go1 – an education platform most recently valued at $3 billion. Now, Go1 co-founders Vu Tran and Andrew Barnes and entrepreneur Gopi Sara have unveiled their next company, OneMRI, which they say is Australia's first and only national provider of whole-body MRI scans. They say it has a similarly sized growth opportunity to their prior start-up. Existing Go1 investors and executives as well as clinicians and radiologists have poured a collective $2.5 million into OneMRI in a seed funding round to fuel its expansion nationally, amid rising demand from 'health curious' individuals who want a full-body scan but don't know where to turn. In between running start-ups, Tran works as a general practitioner, and he said in an interview that OneMRI had been born out of a frustration in not knowing how or where to refer patients for MRI scans. 'It's not covered by Medicare, and no one is catering for it,' Tran said. 'There are all these machines out there that are underutilised, and there are a lot of people out there who want MRI scans. We're that bridge. 'I've been a GP for 10 years and patients are more interested in wellness and their healthcare than they've ever been. And unfortunately, there's a lot of focus in the Medicare system on sick care, not necessarily health care.' Barnes spent nearly a decade as Go1 CEO before stepping down in August last year, though he still spends some time working at the company and he remains on its board. He started Go1 with Tran, a schoolmate, and Chris Hood in 2015 and that same year they were accepted into the Silicon Valley start-up accelerator Y Combinator. More than 10,000 organisations now use Go1 for staff training, and 50 million registered users have completed courses on the platform. Go1 executives are reported to be mulling an IPO and the company has an ambition to reach 1 billion learners globally.
The Age
a day ago
- The Age
They built a billion-dollar start-up from their garage. Now they're going again
They created one of Australia's most valuable technology start-ups in a Brisbane garage – Go1 – an education platform most recently valued at $3 billion. Now, Go1 co-founders Vu Tran and Andrew Barnes and entrepreneur Gopi Sara have unveiled their next company, OneMRI, which they say is Australia's first and only national provider of whole-body MRI scans. They say it has a similarly sized growth opportunity to their prior start-up. Existing Go1 investors and executives as well as clinicians and radiologists have poured a collective $2.5 million into OneMRI in a seed funding round to fuel its expansion nationally, amid rising demand from 'health curious' individuals who want a full-body scan but don't know where to turn. In between running start-ups, Tran works as a general practitioner, and he said in an interview that OneMRI had been born out of a frustration in not knowing how or where to refer patients for MRI scans. 'It's not covered by Medicare, and no one is catering for it,' Tran said. 'There are all these machines out there that are underutilised, and there are a lot of people out there who want MRI scans. We're that bridge. 'I've been a GP for 10 years and patients are more interested in wellness and their healthcare than they've ever been. And unfortunately, there's a lot of focus in the Medicare system on sick care, not necessarily health care.' Barnes spent nearly a decade as Go1 CEO before stepping down in August last year, though he still spends some time working at the company and he remains on its board. He started Go1 with Tran, a schoolmate, and Chris Hood in 2015 and that same year they were accepted into the Silicon Valley start-up accelerator Y Combinator. More than 10,000 organisations now use Go1 for staff training, and 50 million registered users have completed courses on the platform. Go1 executives are reported to be mulling an IPO and the company has an ambition to reach 1 billion learners globally.
Herald Sun
6 days ago
- Herald Sun
Imagion teams up with Wayne State University for AI push into cancer detection
Imagion to collaborate with MRI experts at Wayne State University to strengthen push into AI-enabled cancer diagnostics Collaboration will establish optimised imaging protocols for Imagion's MagSense molecular-imaging-agent tech Bolsters relationship Imagion has with Siemens Healthineers, the leading manufacturer of MRI equipment Special Report : Imagion Biosystems has strengthened its push into AI-enabled cancer diagnostics through a new collaboration with leading MRI experts at Wayne State University School of Medicine in the US. Imagion Biosystem (ASX:IBX) has signed a collaborative service agreement with Dr Mark Haacke and Dr Sagar Bush to establish optimised imaging protocols for its proprietary MagSense molecular imaging agent technology. The collaboration further bolsters the existing relationship Imagion has with Siemens Healthineers, the world's leading manufacturer of MRI equipment. Both researchers have had a long-standing collaboration with Siemens and are equipped with its top-of-the-line scanners. The research will focus on quantitative MRI sequences compatible with Siemens and other commercially available MRI scanners. By combining advanced quantitative imaging with the MagSense agents, Imagion aims to enable AI-based interpretation and deliver more accurate and precise data cancer detection and patient care. With Siemens' backing, Imagion plans to incorporate the optimised MRI sequences developed by the leading researcher into its upcoming phase II clinical trial for its HER2 breast cancer imaging agent. Other key objectives of the collaborative service agreement also include: Determining the lowest dose of the MagSense imaging agent to achieve detection Establish MRI sequences and protocols optimised for MagSense Transferring the optimised protocols to clinical sites for use in the planned MagSense HER2 Phase 2 study Using quantitative imaging techniques that could net AI compatible image data to improve diagnostic accuracy 'Exciting development for the medical imaging field' Haacke has been a pioneer in the field of quantitative MRI for decades. Collaboration with his team is set to lay the foundation for future automated analysis of MagSense images using AI. By implementing quantitative MR imaging techniques, Imagion said the specific signature of MagSense imaging agents will be uniquely detectable in affected tissue. By applying advanced post-processing techniques and AI interpretation to these images, MagSense has potential to enable not only automatic detection and differentiation of normal versus cancerous tissue, but also improved staging, tracking and treatment monitoring. 'Imagion's MagSense imaging agents are a very exciting development for the medical imaging field as it finally brings molecular specificity to MRI,' said Haacke. 'I have spent decades developing quantitative, high-resolution imaging to identify new biomarkers and explore disease etiology. 'Working with Imagion is a natural extension of that work, adding increased specificity to the already high resolution and sensitivity of MRI and powering the future of AI-based diagnostics.' Listen : Tim Boreham interviews IBX Solving a key barrier holding back AI diagnostics Imagion said conventional MRI, while producing excellent images of soft tissue, is qualitative by nature. This means it relies on subjective interpretation by radiologists to make a diagnostic determination based on differences in contrast of the various tissues. As a result, imaging findings still require confirmatory biopsies to achieve diagnostic certainty, creating challenges in analysing small lesions or early-stage disease. The lack of specificity is considered a fundamental hurdle for radiologic AI models, limited in their diagnostic capability due to subjectivity of the training data and accuracy of the readers' interpretation. Quantitative imaging, on the other hand, provides specific information about tissue characteristics on a pixel-by-pixel basis. These imaging techniques can measure precise amounts of elements such as iron, water, calcium, or fat in each region of interest. Imagion said that combining quantitative MRI sequences with its MagSense imaging agent could overcome one of the biggest obstacles to AI in medical imaging. MagSense particles attach to cancer cells, creating a unique, measurable signal that can be distinguished from healthy tissue automatically. This could lead to earlier and more accurate cancer diagnoses, reduce differences in how individual radiologists interpret scans, and make advanced imaging available beyond specialised medical centres The company said including these quantitative sequences in its phase II trial for HER2 breast cancer will accelerate development of AI diagnostics by providing early data to train and refine AI models. Exciting time for Imagion Imagion chief business officer Ward Detwiler said the company was very excited to have the collaboration and support of Haacke's research team. 'Dr Haacke literally wrote the book on MRI, which anyone in the MRI space will recognise as required reading,' he said. 'Combining their knowledge and expertise in quantitative MRI with the specificity of our targeted MagSense imaging agents, we believe we can significantly improve the diagnostic utility of the images by introducing quantitative data to enable precise, AI-based detection.' This article was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Imagion teams up with Wayne State University for AI push into cancer detection
